Home 9 Heart Failure 9 EP.2 – Potential Treatment Options with a Focus on Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors in Patients with Heart Failure with Preserved Ejection Fraction – Prof. Michael Böhm

EP.2 – Potential Treatment Options with a Focus on Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors in Patients with Heart Failure with Preserved Ejection Fraction – Prof. Michael Böhm

October 14, 2022

Episode 2 – Potential Treatment Options with a Focus on Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors in Patients with Heart Failure with Preserved Ejection Fraction

We are joined by Prof. Michael Böhm. He is the director of the Clinic for Internal Medicine III and Chief of Cardiology at the University of the Saarland University in Germany. He has a special interest in pathophysiology and treatment of heart failure and has been the principal investigator of several multi-centre clinical trials. He has written more than 700 original papers, book chapters and review articles and is the past president of the German Society of Cardiology.

In this episode, we will discuss the latest promising results of sodium-glucose cotransporter-2 (SGLT-2 inhibitor) empagliflozin in the EMPEROR-Preserved trials. In the previous podcast with Prof. Anker, we heard that this class of drug is offering more options to patients and clinicians so we will explore this in more detail with Prof. Böhm.

Test your knowledge Ep.2

Thank you for watching. Please click one answer from the drop down menu below. Good luck!

1) The EMPEROR-Preserved study looked at the effects of empagliflozin on heart failure patients with preserved ejection fraction. What was the percentage of ejection fraction above which any patient could be considered for this trial?

2) Clinicians are often concerned about treating some patients, particularly the elderly and those with impaired kidney function, due to the impacts of SGLT-2 inhibitors on sodium levels. Empagliflozin can be safely given to patients with a low eGFR (estimated glomerular filtration rate). What is the lowest level of eGFR that can be treated with empagliflozin?

Reference link:

https://www.nejm.org/doi/full/10.1056/NEJMoa2107038

“This series of medical educational podcasts and associated materials have been sponsored by Boehringer Ingelheim and Lilly Alliance (The Alliance). The Alliance had no influence over the agenda, programme development, content or selection of the faculty. Editorial and content decisions were made solely by Oruen Limited, and faculty chosen by Oruen Limited”.

“Not intended for US & UK based healthcare professionals”.

Available now to stream on your favourite platform: